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Botulinurn neurotoxin type D and exoenxyme C3 have been separately purified from Clostridium botulinurn strain D-1873 
to apparent homogeneity. Both ADP-ribosylated a rat liver cytosolic protein of 24 kDa. The N-terminal amino acid se- 
quence of C3 was determined and showed a low degree of homology with those of the light and heavy chains of neurotox- 
ins of various types which have been reported previously. However, a polyclonal antibody raised against C3 cross-reacted 
with the light chains, but not with the heavy chains, of type Cl and D neurotoxins. Furthermore, a monoclonal antibody 
recognizing the light chains of type Cl and D neurotoxins interacted with C3. These results suggest hat the light chain 
of type Cl or D neurotoxin and exoenxyme C3 share at least one epitope in common with each other. 
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1. INTRODUCTION 
Botulinum neurotoxin is a potent exotoxin pro- 
duced by Clostridium botulinum and has been 
classified into seven groups (types A-G) on the 
basis of antigenicity [ 11. The molecular masses of 
all of the types are approx. 150 kDa. They consist 
of a single polypeptide chain, which is nicked by 
the action of proteases released from the 
organisms or artificially added. The nicked 
neurotoxin is composed of two polypeptide chains, 
viz. the heavy (approx. 100 kDa) and light (ap- 
prox. 50 kDa) chains, which can be separated from 
each other by disulfide reduction. It has been pro- 
posed that the neurotoxin shows toxic activity 
through inhibition of acetylcholine release at 
peripheral synapses [l]. Detailed mechanisms of 
inhibition of acetylcholine release, however, have 
not been well elucidated. 
Recently, botulinum type Cl and D neurotoxins 
have been shown to ADP-ribosylate GTP-binding 
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proteins of 21-26 kDa [2-41. On the other hand, 
it has been reported that ADP-ribosyltransferase 
activity may originate from another enzyme, ex- 
oenzyme C3, produced by the same bacteria [5] 
and, therefore, it has been proposed that ADP- 
ribosylation is not relevant o the neurotoxicity [6]. 
Here, we performed an investigation of im- 
munoreactivity between botulinum neurotoxin 
type Cl or D and exoenzyme C3, together with a 
comparison of their N-terminal amino acid se- 
quences in order to ascertain whether they are 
structurally related to each other. The present 
paper describes several lines of evidence for the 
presence of at least one common epitope in both 
type Cl and D neurotoxins and exoenzyme C3. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
[3ZP]NAD (800 Ci/mmol) was purchased from New England 
Nuclear; QAE-Sephadex A-50, Sephadex G-75 and G-200, 
Mono Q and S from Pharmacia; DEAE-cellulose, affigel- 
protein A and 3,3’-diaminobenzidine from Brown, Bio-Rad 
and Wako (Osaka), respectively; and peroxidase-conjugated 
anti-mouse and anti-rabbit IgGs from Dakopatt. 
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2.2. Assay for ADP-ribosylation 
ADP-ribosylation was performed according to Matsuoka et 
al. [7] using rat liver cytosolic proteins as substrates. 
2.3. SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed in the presence of 0.1% SDS on 8 or 15% 
polyacrylamide gels as in [8] using bovine serum albumin 
(67 kDa), ovalbumin (45 kDa), chymotrypsinogen A (26 kDa) 
and myoglobin (17 kDa) as molecular mass standards. Gels 
were stained with Coomassie brilliant blue R-250 [9] and sub- 
jected to autoradiography. 
2.4. Purification of botulinurn type Cl and D neurotoxins and 
exoenzyme C3 
Botulinum type Cl and D neurotoxins were purified from 
culture supernatants of C. botulinurn strain C-Stockholm and 
strain D-1873, respectively, as described [lo]. 
Exoenzyme C3 was purified from the culture supernatant of 
strain D-1873. Ammonium sulfate was added to the superna- 
tant to 55% saturation. The resulting pellet was collected by 
centrifugation, suspended in borax-phosphate buffer (42 mM 
NarB407-22 mM NaHzP04, pH 8.0) and applied to a column 
(6.5 x 42 cm) of Sephadex G-75 previously equilibrated with 
the same buffer, which was also employed in developing of the 
column. Fractions containing C3 were pooled and applied to a 
column (2.2 x 55 cm) of QAE-Sephadex A-50 previously 
equilibrated with the above buffer. C3 was detected in the 
breakthrough fractions. Fractions containing C3 were pooled 
and applied to a column (0.5 x 5 cm) of Mono S previously 
equilibrated with 20 mM phosphate buffer @H 7.5). After 
washing the column with the same buffer, adsorbed materials 
were eluted with a linear gradient of O-O.5 M NaCl. Fractions 
containing C3 were pooled and applied to a column (2.2 x 
84 cm) of Sephadex G-75 previously equilibrated with 20 mM 
Tris-HCl (pH 7.5) and the column developed with the same buf- 
fer. A single peak of C3 was eluted, which was superimposable 
with a protein peak. Fractions containing C3 were pooled and 
used as a preparation of purified C3. The purified C3 gave a 
single band on SDS-PAGE, suggesting apparent homogeneity. 
2.5. Determination of N-terminal amino acid sequence of 
exoenzyme C3 
The N-terminal amino acid sequence of C3 was determined 
on an Applied Biosystems 470A automatic protein sequencer 
and a 120A phenylthiohydantoin derivative analyzer. 
2.6. Enzyme-linked immunosorbent assay (ELBA) 
ELISA for detection of antibody was carried out as described 
by Oguma et al. [ll] except that peroxidase-conjugated anti- 
mouse or anti-rabbit IgG was used as second antibody. Perox- 
idase reaction was performed at room temperature for 30 min 
in 10 mM citrate-25 mM NazHP04 using both 
2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic a id) diam- 
monium salt (0.2 mg/ml) and Hz02 (0.02%) as substrates. 
Subsequently, the absorbance at 405 nm was measured. 
2.7. Preparation of monoclonal antibody 
Methods of immunization, details of formation and cloning 
of hybridoma cell lines and preparation of ascites fluid have 
been described 1121. In this study, we employed five monoclonal 
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antibodies, two (N-CDA-5 and N-CDA-135) of which are reac- 
tive with the light chains of type Cl and D neurotoxins, the 
other three (N-CDA-14, N-CDA-69, N-CDA-175) being reac- 
tive with the heavy chains [12]. Each monoclonal antibody was 
used after isolation from ascites fluids by two stepwise 
chromatographies on Mono Q and Mono S columns: ascites 
fluids were diluted IO-fold with 20 mM triethanolamine-HCl 
(pH 7.7) and applied to a column (0.5 x 5 cm) of Mono Q 
previously equilibrated with the same buffer. After extensive 
washing of the column with the same buffer, adsorbed antibody 
was eluted with a linear gradient of O-O.5 M NaCl. Fractions 
containing antibody were dialyzed against 20 mM N,N- 
bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (Bes)-NaOH 
(PH 6.0) and applied to a column (0.5 x 5 cm) of Mono S 
previously equilibrated with 20 mM Bes-NaOH (pH 6.0). Ad- 
sorbed antibody was eluted with a linear gradient of O-O.25 M 
NaCl. Fractions containing antibody were pooled and used as 
a purified monoclonal antibody preparation. Detection of an- 
tibody was performed by ELISA as described above. 
2.8. Preparation of polyclonal antibodies against botulinurn 
type D neurotoxin and exoenzyme C3 
Rabbit antiserum against botulinum neurotoxin type D was 
prepared as in [l I]. Anti-exoenzyme C3 serum was prepared as 
follows: C3 (1OOrg) was emulsified with an equal volume of 
Freund’s incomplete adjuvant and injected subcutaneously. An 
initial injection was followed by intravenous boosters of 20 cg 
each without adjuvant at the third and each subsequent weeks. 
Anti-neurotoxin and anti-C3 IgGs were isolated from their 
respective rabbit antisera by chromatography on Affigel- 
protein A (antibody purification kit MAPS II, Bio-Rad) before 
use. 
2.9. Immunoblot analysis 
lmmunoblotting was performed according to Towbin et al. 
[13] with peroxidase-conjugated anti-mouse or anti-rabbit IgG 
as second antibody and both Hz02 and 3,3’-diaminobenzidine 
as peroxidase substrates. 
2.10. Protein determination 
Protein was determined by the method of Lowry et al. [14] 
using bovine serum albumin as a standard. 
3. RESULTS AND DISCUSSION 
Recently, two conflicting proposals concerning 
ADP-ribosylation have been presented; one view- 
point considers botulinum neurotoxin to possess 
ADP-ribosyltransferase activity [2-41, whereas the 
other suggests that this activity originates from ex- 
oenzyme C3 rather than from neurotoxin [5,6]. In 
order to clarify this discrepancy, we isolated both 
botulinum type D neurotoxin and exoenzyme C3 
from culture supernatants of the same strain, 
D-1873, and measured their ADP-ribosyl- 
transferase activities. Highly purified preparations 
of neurotoxin and C3 gave two bands of 50 and 
100 kDa, and a single band of 25 kDa, respective- 
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Fig. 1. ADP-ribosylation of 24 kDa protein of rat liver cytosol 
by botulinum neurotoxin type D (10 /g/ml) and exoenzyme C3 
(1 pg/ml). Electrophoresis was carried out on 15% 
polyacrylamide gel in the presence of 0.1% SDS. 
ly, on SDS-PAGE (not shown). Both the purified 
neurotoxin and C3 were found to ADP-ribosylate 
a protein of 24 kDa among rat liver cytosolic pro- 
teins (fig.1) although the activity of the former 
Table 1 
preparation was less than 1% of that of the latter. 
Although one cannot ascertain whether the 
neurotoxin would actually exhibit ADP- 
ribosyltransferase activity, we examined the 
possibility of structural similarity existing between 
the neurotoxin and C3. 
Firstly, the N-terminal amino acid sequence of 
C3 was determined and compared with those 
reported for both chains of neurotoxins of several 
types [ 15,161. As shown in table 1, little homology 
was detectable between C3 and any of the chains of 
neurotoxins of various types, at least with respect 
to comparisons of N-terminal amino acid se- 
quences. 
Secondly, immuno-crossreactivity between the 
neurotoxin and C3 was examined by immunoblot- 
ting using five monoclonal antibodies raised 
against the neurotoxin (fig.2) and polyclonal an- 
tibody against C3 (fig.3). Among the monoclonal 
antibodies used, one (N-CDA-5) which commonly 
reacts with the light chain components of type Cl 
and D neurotoxins [12], recognized C3 (fig.2). In 
contrast, all monoclonal antibodies specific for the 
heavy chains showed little crossreactivities with C3 
(fig.2). The fact that polyclonal antibody raised 
against ype D neurotoxin was able to recognize C3 
(not shown) supports the above observation on the 
reactivity of anti-light chain monoclonal antibody. 
Furthermore, it was found that anti-C3 polyclonal 
antibody recognized not only C3 but also the light 
N-terminal amino acid sequences of exoenzyme C3 and botulinum neurotoxins 
Protein 
c3 
LC 
Type Aa 
Type Ba 
Type Cb 
Type Ea 
HC 
Type A” 
Type Ba 
Type En 
Amino acid sequence 
1 10 20 
A-Y-S -N-T -Y-Q-E-F -N-T -N-I -D-Q-A-K-A- -G-N-A-Q- 
P-F-V-N-K-Q-F-N-Y-K-D-P-V-N-G-V-D- 
P-V-T -1 -N-N-F -N-Y -N-D-P -1 -D-N-N- 
-1 -T-I -N-N-F -N-Y-S -D-P -V-D-N-K-N-I -L-Y-L -D-T -H-L - 
P- -K-I -N-S -F-N-Y-N-D-P-V-N-D-R-T-I -L-Y-I - 
A-L-N-D-L-C-I -K-V-N-N-I -D-L-K-F- 
A- -P-G-I -C-I -D-V-D-N-E -D-L-F -F -I -A-D- 
K-S_ _ -I -C-I -E-I -N-N-G-E-L-F_ 
a Data from [15] 
b Data from [16] 
LC and HC: light and heavy chain, respectively, of neurotoxin 
85 
Volume 252, number 1,2 FEBS LETTERS July 1989 
Fig.2. Immunoblot analyses of exoenzyme C3 by using 
respectively, of neurotoxin. 
monoclonal antibodies reactive with botulinum type Cl and D 
neurotoxins (N-CDA-5, N-CDA-135, N-CDA-14, N-CDA-69, 
N-CDA-175). C3 (5 pg) was electrophoresed on 15% 
polyacrylamide gel under reducing conditions in the presence of 
0.1% SDS. Immunoblotting was performed as in [13]. LC and 
HC: monoclonal antibodies specific for light and heavy chain, 
chains of type Cl and D neurotoxins, whereas it 
was unable to do so in the case of the heavy chains 
(fig.3). The results on the reactivity of anti-C3 
polyclonal antibody appear to be inconsistent with 
those reported by Rosener et al. [5] and Rubin et 
al. [17] that polyclonal antibody against C3 was 
unable to recognize type Cl neurotoxin. The fact 
that anti-C3 antiserum, reported by Rosener et al. 
PI, almost completely inhibited the ADP- 
ribosyltransferase activity of C3 at a dilution of 
1: 1000, whereas our anti-C3 antibody showed on- 
ly about 20% inhibition at almost the same dilu- 
tion (not shown), would suggest the possibility that 
these two anti-C3 polyclonal antibodies may 
recognize different epitopes in the C3 molecule, 
although the reason for the discrepancy has not 
been elucidated. 
In conclusion, the light chains of botulinurn type 
Cl and D neurotoxins and exoenzyme C3 have at 
least one common antigenic determinant, perhaps 
present in the interiors of their amino acid se- 
quences. Our preliminary result that N-CDA-5 
monoclonal antibody recognizing C3 is unable to 
inhibit ADP-ribosyltranferase activity of C3 would 
imply that common epitope(s) may be present out- 
side the active site in C3. Whether or not 
Fig.3. Immunoblot analyses of botulinum type Cl and D 
neurotoxins and exoenzyme C3 by using polyclonal antibody 
Immunoblotting was according to [13]. 
against C3. Both neurotoxins (5 ,ug each) and C3 (5 pg) were 
electrophoresed on 8 and 15% polyacrylamide gel, respectively, 
under reducing conditions in the presence of 0.1% SDS. 
botulinum neurotoxin has intrinsic ADP- 
ribosyltransferase activity remains unclear. 
Analyses of the active sites for ADP- 
ribosyltransferase activity of the neurotoxin and 
C3, together with determination of the amino acid 
sequence(s) of common epitope(s), would help to 
clarify this point. 
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